Australia's largest stock trading and investment forum Australia's #1 stock forum

ALT

0.00%

0.5¢ analytica limited

Ann: AGM Chairman's Address and CEO Presentation, page-4

First 4 Last

Share
Profile

Follow
bevter

15,831 Posts.

216

01/12/17

09:20

Post #: 29278919
Share
Originally posted by twh_11 ↑

Hi all

My notes on today’s AGM

All objectives to enable the “Deal” have been completed no barriers are in the way.

The NY investment bank engaged to broker the deal has commenced proceedings.

Meetings are held weekly with the Bank including one scheduled for tonight.

The chosen investment bank is a big player in this space.

Very few if any ASX biotech companies would have access to this type of investment bank.

Only paid on results.

There is nothing close in the global market that matches the pericoach and the now collected data they have.

Big players like Google and Apple could be potentially interested due to the health data analytics they have collected.

Board has instructed that all options are on the table e.g global licensing deal for both products or total sale of company.

Deals typically take 3-6 months to achieve, but that is not a definitive timeframe for this.

Dr Peter Corr is the man to get the best deal possible for all share holders. Other ASX boards are envious of who is now on the ALT board.

Next six months will be the most exciting in the companies history according to Geoff.

Past barriers for the sale of the auto start may be on the turn as a the distribution company has been bought out by a major US company and could now package the auto start with pumps for example which has been a problem to date with competitors.

Gladstone Hosptal now using the product. Good feed back to date and some other hospitals in NSW.

pericoach on the cusp of being approved for other conditions.

Other interesting tidbits

Director fees have not increased in 5 years

CEO has not had a payrise in 7.

All ALT staff and board travel economy class

No concern about 3 billion shares on register. Chair could do a consolidation tomorrow if he wanted.

Have enough cash till to last next year and options due early next. R & D tax refund is still available also.

Chair said the extended placement voted on would unlikely ever be required and is there to enable the deal.

Lots of questions asked by share holders.

Mood was positive and not hostile.

Chair acknowledged long term holders and the fact that little return has been seen.

Pericoach has cost 25 million to bring to market and has taken 10 years.

Chair believes share holders will be smiling in the near future.

Next six months will be telling, the chair said this may be the last AGM.

Chair would like to prove ASX wrong.

The board is aware of hot copper and this forum.

The meeting ended with a round of applause.

I have attended a few of these meeting now and left feeling quiet positive about the potential for 2018.

Expand

Thx twh, very good report.
$25m and it doesn't even have a motor
ALT Price at posting: 0.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

CXM

'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 30 more messages in this thread...

First 4 Last

Add ALT (ASX) to my watchlist

Ann: AGM Chairman's Address and CEO Presentation, page-4

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects